Day: February 28, 2021

Admiral Markets AS unaudited 12 months financial results of 2020

Written by Customer Service on . Posted in Public Companies.

In 2020, Admiral Markets AS set a profit record of operation2020 marked Admiral Markets AS’ most successful year. The company’s net profit was 20.3 million euros, which is 340% more than the year before. The volume of transactions increased by 110% during the year.Admiral Markets AS’ net income increased to 47.1 million euros in the past year. In 2019, this figure was 23.2 million euros. The net profit margin in 2020 was 43% (2019: 20%). In 2020, Admiral Markets AS’ customers collectively made 66.9 million transactions, compared to the previous year, when the corresponding figure was 31.8 million.Sergei Bogatenkov, Chairman of the Management Board of Admiral Markets AS, stated that last year’s record results brought the company significantly closer to the goal set for 2030 – to offer financial freedom to 10 million customers....

Continue reading

Admiral Markets AS 2020. aasta 12 kuu auditeerimata majandustulemused

Written by Customer Service on . Posted in Public Companies.

Admiral Markets AS püstitas 2020. aastal tegutsemisaja kasumirekordi2020. aasta oli Admiral Markets AS tegutsemisaja edukaim. Ettevõtte puhaskasum oli 20,3 miljonit eurot, mida on 340% rohkem kui aasta varem. Tehingute maht kasvas aastaga 110%. Admiral Markets AS-i kauplemise netotulu kasvas möödunud aastal 47,1 miljoni euroni. 2019. aastal oli vastav näitaja 23,2 miljonit eurot. Puhaskasumi marginaal oli 2020. aasta kokkuvõttes 43% (2019: 20%). 2020. aastal tegid Admiral Markets AS kliendid 66,9 miljonit tehingut, võrdluses aasta varasemaga, mil vastav näitaja oli 31,8 miljonit. Admiral Markets AS juhatuse esimees Sergei Bogatenkov ütles, et möödunud aasta rekordtulemused viisid ettevõtte märgatavalt lähemale 2030. aastaks seatud eesmärgile- pakkuda finantsvabadust 10 miljonile kliendile. “Loomulikult oleme äriliste tulemuste üle väga...

Continue reading

BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A

Written by Customer Service on . Posted in Public Companies.

Molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that progresses rapidly, results in severe and largely irreversible neurological injury, and has a high infant mortality rate; median overall survival age is about four yearsClinical trials with NULIBRY or recombinant cPMP showed a meaningful increase in overall survival compared to a natural history studyNULIBRY is BridgeBio’s first FDA-approved therapeuticPALO ALTO, Calif., Feb. 28, 2021 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio) and affiliate Origin Biosciences, Inc. (Origin) today announced the U.S. Food and Drug Administration (FDA) has approved NULIBRY™ (fosdenopterin) for Injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A. This is...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.